{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:20:17Z","timestamp":1789881617157,"version":"4.0.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only treatment option with curative potential in patients with myelofibrosis (MF). The aim of our study was to evaluate the safety of splenectomy before alloHSCT in MF patients who failed to achieve significant spleen response after ruxolitinib therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Splenectomy was performed in 12 patients for alloHSCT with myelofibrosis-primary (6 patients), post-polycythemia vera (3 patients). or postessential thrombocythemia (3 patients) between 2016 and 2018. The patients were prospectively included in the study if persistence of splenomegaly \u2265 25 cm was documented after at least 3 months of ruxolitinib therapy. In eight patients subsequent alloHSCT was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Median length of hospital stay was 11 (8-30) days, median follow-up after splenectomy was 20.0 (0.6-31.1) months. No deaths were documented, perioperative morbidity was 50%. Three patients experienced portal vein thrombosis and one experienced splenic vein thrombosis. One patient developed pancreonecrosis and subdiaphragmatic abscess. Mean leukocyte count was significantly higher 1 month after splenectomy than before, 10.7 \u00b1 1.7 versus 6.9 \u00b1 2.3 \u00d7 109\/L (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.03). Platelets rate significantly elevated starting Day + 7 after splenectomy (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.01). Median time between splenectomy and alloHSCT was 2.6 (0.17-4.5) months. All patients achieved engraftment. In early posttransplant period no cases of severe sepsis, intraabdominal infections were documented. One patient died after alloHSCT due to thrombotic microangiopathy. Seven patients are alive in disease complete remission. No relapses after alloHSCT were observed. Two-year overall survival in the whole group is 90% (95%CI 98-43%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Splenectomy before alloHSCT might be a promising option in patients who failed to achieve significant spleen response after ruxolitinib therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T10:42:16Z","timestamp":1554547336000},"page":"140-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Splenectomy following JAK1\/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation"],"prefix":"10.4103","volume":"12","author":[{"given":"Maria Vladimirovna","family":"Barabanshikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Nikolaevich","family":"Zubarovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vjacheslav Mikhailovich","family":"Savrasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey Jurjevich","family":"Korolkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim Valentinovich","family":"Baykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Vjacheslavovna","family":"Botina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Jurjevna","family":"Vlasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Sergeevich","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Igorevna","family":"Darskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Vladislavovna","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris Vladimirovich","family":"Afanasyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2019.03.001_b0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1159\/000477253","article-title":"Clinical correlates and prognostic significance of IL-8, sIL-2R, and immunoglobulin-free light chain levels in patients with myelofibrosis","volume":"40","author":"Barabanshikova","year":"2017","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.hemonc.2019.03.001_b0010","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.03.001_b0015","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.03.001_b0020","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.03.001_b0025","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2019.03.001_b0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2019.03.001_b0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2012.249","article-title":"Effects of spleen status on early outcomes after hematopoietic cell transplantation","volume":"48","author":"Akpek","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2019.03.001_b0040","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"Alchalby","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2019.03.001_b0045","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3324\/haematol.2016.146811","article-title":"Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"Hart","year":"2016","journal-title":"Hematologica"},{"key":"10.1016\/j.hemonc.2019.03.001_b0050","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood.V120.21.801.801","article-title":"Long-term safety, efficacy, and survival findings from comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (bat) for the treatment of myelofibrosis (mf)","volume":"120","author":"Cervantes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.03.001_b0055","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.hemonc.2019.03.001_b0060","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.03.001_b0065","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.03.001_b0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.03.001_b0075","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.03.001_b0080","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.03.001_b0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, posttransplantation cyclophosphamide to promote graft\u2013host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol Res"},{"key":"10.1016\/j.hemonc.2019.03.001_b0090","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2019.03.001_b0095","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/leu.2015.75","article-title":"Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies","volume":"29","author":"Olsson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2019.03.001_b0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3324\/haematol.2010.038299","article-title":"Pathophysiology of thrombosis in myeloproliferative neoplasms thrombosis in myeloproliferative neoplasms: few answers and many new questions","volume":"96","author":"Landolfi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2019.03.001_b0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications, and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2019.03.001_b0110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/01.sla.0000143303.10884.58","article-title":"Platelet kinetics and decreased transfusion requirements after splenectomy for hematologic malignancy","volume":"240","author":"Berman","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.hemonc.2019.03.001_b0115","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3892\/br.2016.755","article-title":"Early prophylactic anticoagulation for portal vein system thrombosis after splenectomy: a systematic review and meta-analysis","volume":"5","author":"Zhang","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.hemonc.2019.03.001_b0120","doi-asserted-by":"crossref","first-page":"E235","DOI":"10.1002\/ajh.25203","article-title":"Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis","volume":"93","author":"Mudireddy","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2019.03.001_b0125","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2019.03.001_b0130","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on myeloid with myeloid metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387619300263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387619300263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201912030-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:29Z","timestamp":1787838029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201912030-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2019.03.001","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}